Clinical observation of herombopag combined with recombinant human thrombopoietin in the treatment of primary immune thrombocytopenia
- VernacularTitle:海曲泊帕联合重组人血小板生成素治疗原发免疫性血小板减少症的临床观察
- Author:
Xing GUO
1
;
Dan ZHAO
2
;
Jinman ZUO
3
Author Information
1. Dept. of Pharmacy，the Second Affiliated Hospital of Bengbu Medical College，Anhui Bengbu 233020，China
2. Dept. of Pharmacy，the Third People’s Hospital of Bengbu，Anhui Bengbu 233099，China
3. Dept. of Hematology，the Second Affiliated Hospital of Bengbu Medical College，Anhui Bengbu 233020，China
- Publication Type:Journal Article
- Keywords:
herombopag;
recombinant human thrombopoietin;
primary immune thrombocytopenia;
clinical efficacy;
safety
- From:
China Pharmacy
2023;34(23):2910-2914
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the clinical efficacy and safety of herombopag combined with recombinant human thrombopoietin （rhTPO） in the treatment of primary immune thrombocytopenia （ITP） in the real world. METHODS A retrospective study was conducted on the patients diagnosed with ITP in the Second Affiliated Hospital of Bengbu Medical College from January 2021 to December 2022. Among them， 98 patients who were treated with a combination of herombopag and rhTPO were included in the observation group， and 157 patients who were treated with rhTPO alone were included in the control group. The changes in platelet count， clinical efficacy， bleeding， platelet transfusion rate and adverse drug reactions before and after treatment were observed and compared between the two groups. RESULTS Since the 8th day of treatment， there was a statistically significant difference in platelet count between the two groups （[ 61.04±13.46）×109 L－1 in observation group， （52.11±12.06）× 109 L－1 in control group] （P＜0.05）， and there also was a statistically significant difference in the peak and stable values of platelet count between the two groups （P＜0.05）. The total effective rates of the observation group and the control group were 79.59% and 66.88%， with cumulative response rates of 81.32% and 68.68%， and median response durations of 8 days and 10 days， respectively； these differences were statistically significant （P＜0.05）. During the treatment period， the bleeding rates of the observation group and control group were 3.06% and 8.28% （P＜0.05）， bleeding events were categorized as grade 1 or 2， and platelet transfusion rates were 31.63% and 40.76%； the differences in bleeding rates and platelet transfusion rates between the two groups was statistically significant （P＜0.05）. The incidences of adverse drug reactions in the two groups were 11.22% and 9.55%， respectively， with no statistically significant difference （P＞0.05）， and no moderate to severe adverse drug reaction was found. CONCLUSIONS The combination of herombopag and rhTPO can significantly increase platelet levels and response rate， and reduce bleeding rate and platelet transfusion rate in ITP patients， with good safety.
